Clinical Trial

Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer

Study acronym: ARC-10
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a phase 2 study to evaluate zimberelimab (AB122) combined with domvanalimab (AB154) in front-line, PD-L1-high, locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC).
Protocol Amendment History 2 changes
notable Trial sites expanded: 39 -> 44 locations 2026-07-30
notable Trial sites reduced: 56 -> 39 locations 2026-04-24
Trial Details
NCT Number NCT04736173
Lead Sponsor Arcus Biosciences, Inc.
Collaborators: Gilead Sciences
Conditions Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer, Squamous Non Small Cell Lung Cancer, Lung Cancer
Enrollment 169 participants
Start Date 2021-02-08
Primary Completion 2027-05 (estimated)
Study Completion 2027-05 (estimated)
Updated on ClinicalTrials.gov 2026-07-29